Table 4.
Descriptive statistics of study population with a measurement of IgA.
| Pancreatic cancer N = 169 n (%) | No pancreatic cancer N = 41,731 n (%) | |
|---|---|---|
| Mean Age (years) (SD) | 60.3 (12.07) | 49.6 (16.10) |
| <55 | 58 (34.32) | 27,142 (65.04) |
| ≥55 | 111 (65.68) | 14,589 (34.96) |
| Gender | ||
| Men | 69 (40.83) | 14,999 (35.94) |
| Women | 100 (59.17) | 26,732 (64.06) |
| SES | ||
| Unclassified/Missing | 27 (15.98) | 7,499 (17.97) |
| Low | 69 (40.83) | 18,137 (43.46) |
| High | 73 (43.20) | 16,095 (38.57) |
| Education | ||
| Missing | 14 (8.28) | 2,358 (5.65) |
| Low | 50 (29.59) | 10,787 (25.85) |
| Middle | 64 (37.87) | 17,734 (42.50) |
| High | 41 (24.26) | 10,852 (26.00) |
| Charlson Comorbidity Index | ||
| 0 | 138 (81.66) | 37,290 (89.36) |
| 1 | 22 (13.02) | 2,950 (7.07) |
| 2 | 7 (4.14) | 856 (2.05) |
| 3+ | 2 (1.18) | 635 (1.52) |
| Mean follow-up time (years) (SD) | 8.8 (5.88) | 16.5 (5.22) |
| Glucose (mmol/L) | ||
| Mean (SD) | 5.50 (1.76) | 5.08 (1.42) |
| <5.60 mmol/L | 96 (56.80) | 25,481 (61.06) |
| 5.60–6.99 mmol/L | 25 (14.79) | 3,990 (9.56) |
| ≥7.00 mmol/L | 11 (6.51) | 1,315 (3.15) |
| Missing | 37 (21.89) | 10,945 (26.23) |
| IgA (g/L) | ||
| Mean (SD) | 2.47 (1.20) | 2.32 (1.20) |
| <3.66 g/L | 151 (89.35) | 37,228 (89.21) |
| ≥3.66 g/L | 18 (10.65) | 4,503 (10.79) |